Hematological Malignancies

P1, N=10, Active, not recruiting, Baylor College of Medicine | Trial completion date: Jul 2026 --> Jul 2027

P=N/A, N=1, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting | N=30 --> 1

P2, N=25, Not yet recruiting, Jennifer Woyach | Initiation date: May 2026 --> Sep 2026

P1, N=46, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2030 --> May 2028 | Trial primary completion date: Feb 2030 --> May 2028

P=N/A, N=50, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Jun 2026 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Jul 2026

P2, N=17, Recruiting, Johns Hopkins All Children's Hospital | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

The children presented with severe pain and vesicular lesions; one had noncontiguous dermatomal involvement. The findings underscore the role of immunosuppression, particularly HIV and leukemia therapy, in atypical HZ presentations.

The final diagnosis was CD20-negative primary intestinal large B-cell lymphoma with a TP53 mutation arising in the context of poorly controlled CD, a combination that, to the best of our knowledge, has not been previously reported in the literature. This case highlights the diagnostic challenges posed by intestinal lymphomas associated with CD and emphasizes the importance of integrating histopathological, immunophenotypic, and molecular findings to achieve an accurate diagnosis and provide prognostic assessment.

The integration of alternative genotype parameterizations and regularized machine learning highlights pathways for future predictive research. However, given the retrospective nature of the study and inherent risks of internal optimism, these scores serve as biologically informed proof-of-concept models that strictly require robust prospective external validation.

DCA revealed that this fusion model offers a significant clinical net benefit for prognostic risk prediction in DLBCL patients over a wide threshold probability range of 0.05-0.900. The fusion model, combining PET/CT deep features with clinical characteristics, is a dependable prognostic tool for DLBCL, holding substantial promise for clinical application and personalized treatment.

The 5‑index risk model demonstrated robust predictive ability in a real‑world setting, providing a reliable basis for personalized treatment decisions in Chinese DLBCL patients undergoing CAR‑T. Future work will focus on further optimizing the model and conducting multi‑regional validation.

Following multidisciplinary consultation, the patient was treated with the bendamustine plus rituximab (BR) regimen. Second, for WM patients with renal AL amyloidosis, choosing BR regimen as the first-line treatment is reasonable. However, during the treatment process, it is essential to closely monitor and actively prevent the adverse effects of this regimen, particularly severe infections which may have fatal consequences.